Resmed
- Short interest
- 0.51%
- −0.04 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 2.9M
- Shares on issue
- 570.128M
Resmed (RMD) Short Interest
Resmed (ASX:RMD) had 0.51% of shares reported as short positions as of 8 Oct 2026, representing 2,884,880 shares. Resmed operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Resmed
ResMed is a global leader in the design, manufacture, and distribution of medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders, including sleep apnea, COPD, and other chronic diseases. The company's core business revolves around providing innovative solutions for improving the quality of life for people with respiratory conditions, holding a significant market share in the sleep apnea treatment market.
Company profile →Resmed (ASX:RMD) has 0.51% of its shares on issue reported as short positions as of 8 Oct 2026, or about 2,884,880 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.16 percentage points. Its highest recorded short interest was 3.10% in October 2014. RMD is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads RMD today
- Zanger BreakoutWatchScore 36rank 299 of 1942
- CAN SLIMWatchScore 25rank 447 of 1541
- Minervini Trend TemplateWatchScore 46rank 344 of 1716
- Crowded-Short BreakoutWatchScore 23rank 228 of 1502
- Quality compoundersTriggeredScore 84rank 10 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
RMD fundamentals
In the year to 30 Jun 2026, Resmed (ASX:RMD) recorded revenue of US$5.7B and net profit after tax of US$1.5B. A year earlier it recorded revenue of US$5.1B and net profit after tax of US$1.4B. Year-on-year growth: revenue +9.9% (FY), EPS +9.7% (TTM). Net margin 26.9%, return on equity 24.3% (FY). Figures are in USD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest RMD news
All news- How Is ResMed Climbing Despite the Tech Slide (ASX:RMD)?
kalkine · 14 Oct 2026
- How Strong Is ASX 200 Stock ResMed's (ASX:RMD) Chart Ahead of Its Update?
kalkine · 13 Oct 2026
- Why Is ResMed (ASX:RMD) Leaning on Capital Returns?
kalkine · 9 Oct 2026
Company details
website
address
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss RMD
Start a research thread or post the first pulse update